Michiyuki Maeda
Overview
Explore the profile of Michiyuki Maeda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, et al.
Leukemia
. 2024 Oct;
39(1):243-247.
PMID: 39433928
No abstract available.
2.
Chiba M, Shimono J, Suto K, Ishio T, Endo T, Goto H, et al.
Blood
. 2023 Dec;
143(14):1379-1390.
PMID: 38142436
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis and limited treatment options. Programmed cell death ligand 1(PD-L1) is recognized to be involved in the pathobiology...
3.
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, et al.
Blood
. 2022 Aug;
140(18):1951-1963.
PMID: 35921533
Adult T-cell leukemia/lymphoma (ATLL) is one of the aggressive peripheral T-cell neoplasms with a poor prognosis. Accumulating evidence demonstrates that escape from adaptive immunity is a hallmark of ATLL pathogenesis....
4.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al.
Blood
. 2021 Nov;
139(10):1541-1556.
PMID: 34818414
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3,...
5.
Maeda M, Tanabe-Shibuya J, Miyazato P, Masutani H, Yasunaga J, Usami K, et al.
Front Microbiol
. 2020 Mar;
11:356.
PMID: 32210945
T cells infected with human T-cell leukemia virus type 1 (HTLV-1) transform into malignant/leukemic cells and develop adult T-cell leukemia (ATL) after a long latency period. The (transactivator from the...
6.
Nakagawa M, Shaffer 3rd A, Ceribelli M, Zhang M, Wright G, Huang D, et al.
Cancer Cell
. 2018 Jul;
34(2):286-297.e10.
PMID: 30057145
Adult T cell leukemia/lymphoma (ATLL) is a frequently incurable disease associated with the human lymphotropic virus type I (HTLV-I). RNAi screening of ATLL lines revealed that their proliferation depends on...
7.
Perera L, Zhang M, Nakagawa M, Petrus M, Maeda M, Kadin M, et al.
Am J Hematol
. 2017 May;
92(9):892-901.
PMID: 28543380
With the emerging success of treating CD19 expressing B cell malignancies with ex vivo modified, autologous T cells that express CD19-directed chimeric antigen receptors (CAR), there is intense interest in...
8.
Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, et al.
PLoS One
. 2016 Mar;
11(3):e0150496.
PMID: 27028595
To develop a new therapeutic monoclonal Antibody (mAb) for Hodgkin lymphoma (HL), we immunized a BALB/c mouse with live HL cell lines, alternating between two HL cell lines. After hybridization,...
9.
Zhang M, Mathews Griner L, Ju W, Duveau D, Guha R, Petrus M, et al.
Proc Natl Acad Sci U S A
. 2015 Sep;
112(40):12480-5.
PMID: 26396258
Adult T-cell leukemia (ATL) develops in individuals infected with human T-cell lymphotropic virus-1 (HTLV-1). Presently there is no curative therapy for ATL. HTLV-1-encoded protein Tax (transactivator from the X-gene region)...
10.
Ju W, Zhang M, Petrus M, Maeda M, Pise-Masison C, Waldmann T
Retrovirology
. 2014 Jun;
11:43.
PMID: 24890041
Background: Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human T-cell lymphotropic virus type 1. While much progress has been made in understanding the mechanisms...